Boston Scientific Corp. (NYSE:BSX) said today that it was given FDA clearance for the two manufacturing changes that were affecting its cardiac defibrillators, and will immediately continue with distribution of Teligen ICDs and Cognis CRT-Ds.
Boston Scientific closed today at $7.14.
source